0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      COVID-19: Health prevention and control in non-healthcare settings

      editorial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Novel coronavirus disease (COVID-19) was first detected in Wuhan City, Hubei Province in China, at the end of 2019 [1]. The virus widely spread to many countries, affecting every continent. On 30 January 2020, the World Health Organization (WHO) declared the outbreak of COVID-19 to be a public health emergency of international concern [2]. At the beginning of March 2020, there were >109 000 confirmed cases and >3800 deaths from COVID-19 [3]. Healthcare workers (HCWs) have an increased risk of contracting COVID-19, but a recent study has reported that other workers may also be exposed to the Coronavirus, including staff in the tourism, retail and hospitality industries, transport and security workers, and construction site workers [4]. Considering the current dynamic situation and the ongoing spread of COVID-19 virus, it is important to provide physicians with information about COVID-19 risk management in non-healthcare settings, which are less familiar with this type of situation. Physicians and other HCWs are generally used to following instructions about containment of infection, while other workers are less accustomed to this. We aim to provide general information about risk management in other workplaces, to minimize the spread of COVID-19 in non-healthcare settings. Physicians, especially those in charge of occupational health services, should provide workers with accurate information and training about COVID-19, to ensure adequate risk perception and to improve compliance with prevention and control measures. COVID-19 is caused by a virus named SARS-CoV-2. Symptoms are generally similar to flu (fever, dry cough, headache, sore throat and runny nose), but ~25% of patients require intensive care and 10% require mechanical ventilation [5,6]. The case-fatality rate is variable and depends on several factors (age, co-morbidity, etc.), but is ~2%. Although several modes of transmission have been identified, the virus is transmitted primarily through large respiratory droplets from close contacts [6,7]. Data on the survival time of the virus in the environment are still poorly understood, but it seems that the SARS-CoV-2 is able to survive for several days [8]. The incubation period varies from 1 to 14 days, with a median of 5–6 days. Therefore, the quarantine period should be around 2 weeks after a close contact with a person with symptoms. The expected number of secondary cases caused by a single person with COVID-19 in a susceptible population (R 0) is 2·2, somewhat higher than seasonal flu (1·0–2·0), but lower than measles (12–18) [4]. A specific vaccine against SARS-CoV-2 is not yet available. In addition to adequate information and training, prevention and protection measures should be implemented in workplaces, to minimize the virus spreading (Table 1). Table 1. Prevention and control measures in non-healthcare settings ➢ Provide information and education about COVID-19 ➢ Stay home in case of symptoms or in case of a suspected transmission of COVID-19 virus (quarantine) ➢ Wash and clean hands with water and soap or with alcoholic solutions ➢ Maintain social distance (1 m) between people ➢ Clean surfaces, objects, clothes, and reduce the sharing of objects ➢ Ensure workplaces ventilation ➢ Do not recommend unnecessary PPE It is vital to emphasize the importance of staying at home and not going to work in the case of flu-like symptoms, to prevent other workers’ exposure. Special attention should be paid to fever (a body temperature above 37·5°C or 99·5°F), cough, sore throat, runny nose and other respiratory symptoms. When exposure to COVID-19 virus may have occurred, the worker should stay home for the quarantine period, monitoring any symptoms. Companies should consider implementing smart working solutions, in which workers can work from home to avoid contact with colleagues, using a computer and an internet connection. Occupational physicians should recommend hand hygiene, an effective measure with minimal costs [8]. Specifically, hands should be washed regularly, using soap and water for 20–40 s. Alternatively, hands can be cleaned with alcohol solution (at least 60% alcohol). Workers should not touch their eyes, nose and mouth to avoid contact with mucous membranes [7]. Cough etiquette is important to reduce the virus spreading, i.e. coughing into a flexed elbow or sneezing into a tissue, that must be immediately disposed of [7]. There is no personal protective equipment (PPE) recommendation for workers in non-healthcare settings. According to the WHO, PPE for COVID-19 virus is recommended only for specific duties in healthcare facilities. Medical mask, gown, gloves or eye protection are not indicated for workers in general settings. However, medical masks should be worn by people with symptoms, to avoid the spreading of droplets [7]. The minimum distance between people (worker–worker, worker–customer) must be at least 1 m (social distance), which prevents droplet transmission [7]. The social distance must be enforced, especially in workplaces with interactions between workers and customers, such as retail stores, hotels, restaurants and any front office activities. In other settings, the social distance is also important, e.g. web meetings instead of face-to-face meetings. Environmental measures must be implemented. It is recommended to frequently clean surfaces (i.e. counters), objects and clothes, and to reduce the sharing of objects. Appropriate ventilation must be ensured in workplaces where there are customers or many workers (i.e. front office activities, open-space offices) [8]. Some workers may be involved in duties that include the handling of cargo or other objects from affected countries, such as shipping or dock workers. Although the COVID-19 virus can survive on surfaces, the use of specific PPE is not recommended but hands should be washed frequently. According to the WHO, contact with goods or products shipped from countries with COVID-19 outbreaks cannot transmit the infection [7]. Italy is the country with the third highest number of COVID-19 cases, after China and South Korea [3]. Many companies have promoted smart working solutions. When smart working solutions could not be implemented workers have been provided with advice about hand hygiene, social distance, daily cleaning and disinfecting of surfaces, and adequate ventilation, to prevent potential contact with droplets. Also, organizational measures have been implemented to avoid overcrowding in workplaces, such as limiting access of customers to front office services.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A novel coronavirus outbreak of global health concern

            In December, 2019, Wuhan, Hubei province, China, became the centre of an outbreak of pneumonia of unknown cause, which raised intense attention not only within China but internationally. Chinese health authorities did an immediate investigation to characterise and control the disease, including isolation of people suspected to have the disease, close monitoring of contacts, epidemiological and clinical data collection from patients, and development of diagnostic and treatment procedures. By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus (CoV) from patients in Wuhan. The genetic sequence of the 2019 novel coronavirus (2019-nCoV) enabled the rapid development of point-of-care real-time RT-PCR diagnostic tests specific for 2019-nCoV (based on full genome sequence data on the Global Initiative on Sharing All Influenza Data [GISAID] platform). Cases of 2019-nCoV are no longer limited to Wuhan. Nine exported cases of 2019-nCoV infection have been reported in Thailand, Japan, Korea, the USA, Vietnam, and Singapore to date, and further dissemination through air travel is likely.1, 2, 3, 4, 5 As of Jan 23, 2020, confirmed cases were consecutively reported in 32 provinces, municipalities, and special administrative regions in China, including Hong Kong, Macau, and Taiwan. 3 These cases detected outside Wuhan, together with the detection of infection in at least one household cluster—reported by Jasper Fuk-Woo Chan and colleagues 6 in The Lancet—and the recently documented infections in health-care workers caring for patients with 2019-nCoV indicate human-to-human transmission and thus the risk of much wider spread of the disease. As of Jan 23, 2020, a total of 835 cases with laboratory-confirmed 2019-nCoV infection have been detected in China, of whom 25 have died and 93% remain in hospital (figure ). 3 Figure Timeline of early stages of 2019-nCoV outbreak 2019-nCoV=2019 novel coronavirus. In The Lancet, Chaolin Huang and colleagues 7 report clinical features of the first 41 patients admitted to the designated hospital in Wuhan who were confirmed to be infected with 2019-nCoV by Jan 2, 2020. The study findings provide first-hand data about severity of the emerging 2019-nCoV infection. Symptoms resulting from 2019-nCoV infection at the prodromal phase, including fever, dry cough, and malaise, are non-specific. Unlike human coronavirus infections, upper respiratory symptoms are notably infrequent. Intestinal presentations observed with SARS also appear to be uncommon, although two of six cases reported by Chan and colleagues had diarrhoea. 6 Common laboratory findings on admission to hospital include lymphopenia and bilateral ground-glass opacity or consolidation in chest CT scans. These clinical presentations confounded early detection of infected cases, especially against a background of ongoing influenza and circulation of other respiratory viruses. Exposure history to the Huanan Seafood Wholesale market served as an important clue at the early stage, yet its value has decreased as more secondary and tertiary cases have appeared. Of the 41 patients in this cohort, 22 (55%) developed severe dyspnoea and 13 (32%) required admission to an intensive care unit, and six died. 7 Hence, the case-fatality proportion in this cohort is approximately 14·6%, and the overall case fatality proportion appears to be closer to 3% (table ). However, both of these estimates should be treated with great caution because not all patients have concluded their illness (ie, recovered or died) and the true number of infections and full disease spectrum are unknown. Importantly, in emerging viral infection outbreaks the case-fatality ratio is often overestimated in the early stages because case detection is highly biased towards the more severe cases. As further data on the spectrum of mild or asymptomatic infection becomes available, one case of which was documented by Chan and colleagues, 6 the case-fatality ratio is likely to decrease. Nevertheless, the 1918 influenza pandemic is estimated to have had a case-fatality ratio of less than 5% 13 but had an enormous impact due to widespread transmission, so there is no room for complacency. Table Characteristics of patients who have been infected with 2019-nCoV, MERS-CoV, and SARS-CoV7, 8, 10, 11, 12 2019-nCoV * MERS-CoV SARS-CoV Demographic Date December, 2019 June, 2012 November, 2002 Location of first detection Wuhan, China Jeddah, Saudi Arabia Guangdong, China Age, years (range) 49 (21–76) 56 (14–94) 39·9 (1–91) Male:female sex ratio 2·7:1 3·3:1 1:1·25 Confirmed cases 835† 2494 8096 Mortality 25† (2·9%) 858 (37%) 744 (10%) Health-care workers 16‡ 9·8% 23·1% Symptoms Fever 40 (98%) 98% 99–100% Dry cough 31 (76%) 47% 29–75% Dyspnoea 22 (55%) 72% 40–42% Diarrhoea 1 (3%) 26% 20–25% Sore throat 0 21% 13–25% Ventilatory support 9·8% 80% 14–20% Data are n, age (range), or n (%) unless otherwise stated. 2019-nCoV=2019 novel coronavirus. MERS-CoV=Middle East respiratory syndrome coronavirus. SARS-CoV=severe acute respiratory syndrome coronavirus. * Demographics and symptoms for 2019-nCoV infection are based on data from the first 41 patients reported by Chaolin Huang and colleagues (admitted before Jan 2, 2020). 8 Case numbers and mortalities are updated up to Jan 21, 2020) as disclosed by the Chinese Health Commission. † Data as of Jan 23, 2020. ‡ Data as of Jan 21, 2020. 9 As an RNA virus, 2019-nCoV still has the inherent feature of a high mutation rate, although like other coronaviruses the mutation rate might be somewhat lower than other RNA viruses because of its genome-encoded exonuclease. This aspect provides the possibility for this newly introduced zoonotic viral pathogen to adapt to become more efficiently transmitted from person to person and possibly become more virulent. Two previous coronavirus outbreaks had been reported in the 21st century. The clinical features of 2019-nCoV, in comparison with SARS-CoV and Middle East respiratory syndrome (MERS)-CoV, are summarised in the table. The ongoing 2019-nCoV outbreak has undoubtedly caused the memories of the SARS-CoV outbreak starting 17 years ago to resurface in many people. In November, 2002, clusters of pneumonia of unknown cause were reported in Guangdong province, China, now known as the SARS-CoV outbreak. The number of cases of SARS increased substantially in the next year in China and later spread globally, 14 infecting at least 8096 people and causing 774 deaths. 12 The international spread of SARS-CoV in 2003 was attributed to its strong transmission ability under specific circumstances and the insufficient preparedness and implementation of infection control practices. Chinese public health and scientific capabilities have been greatly transformed since 2003. An efficient system is ready for monitoring and responding to infectious disease outbreaks and the 2019-nCoV pneumonia has been quickly added to the Notifiable Communicable Disease List and given the highest priority by Chinese health authorities. The increasing number of cases and widening geographical spread of the disease raise grave concerns about the future trajectory of the outbreak, especially with the Chinese Lunar New Year quickly approaching. Under normal circumstances, an estimated 3 billion trips would be made in the Spring Festival travel rush this year, with 15 million trips happening in Wuhan. The virus might further spread to other places during this festival period and cause epidemics, especially if it has acquired the ability to efficiently transmit from person to person. Consequently, the 2019-nCoV outbreak has led to implementation of extraordinary public health measures to reduce further spread of the virus within China and elsewhere. Although WHO has not recommended any international travelling restrictions so far, 15 the local government in Wuhan announced on Jan 23, 2020, the suspension of public transportation, with closure of airports, railway stations, and highways in the city, to prevent further disease transmission. 16 Further efforts in travel restriction might follow. Active surveillance for new cases and close monitoring of their contacts are being implemented. To improve detection efficiency, front-line clinics, apart from local centres for disease control and prevention, should be armed with validated point-of-care diagnostic kits. Rapid information disclosure is a top priority for disease control and prevention. A daily press release system has been established in China to ensure effective and efficient disclosure of epidemic information. Education campaigns should be launched to promote precautions for travellers, including frequent hand-washing, cough etiquette, and use of personal protection equipment (eg, masks) when visiting public places. Also, the general public should be motivated to report fever and other risk factors for coronavirus infection, including travel history to affected area and close contacts with confirmed or suspected cases. Considering that substantial numbers of patients with SARS and MERS were infected in health-care settings, precautions need to be taken to prevent nosocomial spread of the virus. Unfortunately, 16 health-care workers, some of whom were working in the same ward, have been confirmed to be infected with 2019-nCoV to date, although the routes of transmission and the possible role of so-called super-spreaders remain to be clarified. 9 Epidemiological studies need to be done to assess risk factors for infection in health-care personnel and quantify potential subclinical or asymptomatic infections. Notably, the transmission of SARS-CoV was eventually halted by public health measures including elimination of nosocomial infections. We need to be wary of the current outbreak turning into a sustained epidemic or even a pandemic. The availability of the virus' genetic sequence and initial data on the epidemiology and clinical consequences of the 2019-nCoV infections are only the first steps to understanding the threat posed by this pathogen. Many important questions remain unanswered, including its origin, extent, and duration of transmission in humans, ability to infect other animal hosts, and the spectrum and pathogenesis of human infections. Characterising viral isolates from successive generations of human infections will be key to updating diagnostics and assessing viral evolution. Beyond supportive care, 17 no specific coronavirus antivirals or vaccines of proven efficacy in humans exist, although clinical trials of both are ongoing for MERS-CoV and one controlled trial of ritonavir-boosted lopinavir monotherapy has been launched for 2019-nCoV (ChiCTR2000029308). Future animal model and clinical studies should focus on assessing the effectiveness and safety of promising antiviral drugs, monoclonal and polyclonal neutralising antibody products, and therapeutics directed against immunopathologic host responses. We have to be aware of the challenge and concerns brought by 2019-nCoV to our community. Every effort should be given to understand and control the disease, and the time to act is now. This online publication has been corrected. The corrected version first appeared at thelancet.com on January 29, 2020
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              COVID-19—New Insights on a Rapidly Changing Epidemic

                Bookmark

                Author and article information

                Journal
                Occup Med (Lond)
                Occup Med (Lond)
                occmed
                Occupational Medicine (Oxford, England)
                Oxford University Press (UK )
                0962-7480
                1471-8405
                April 2020
                20 April 2020
                20 April 2020
                : 70
                : 2
                : 82-83
                Affiliations
                School of Medicine and Surgery, University of Milano-Bicocca , Monza, Italy
                Author notes
                Author information
                http://orcid.org/0000-0001-6807-6819
                Article
                kqaa048
                10.1093/occmed/kqaa048
                7188129
                32311040
                98c07065-f752-4401-b040-e8a8ae63e1a5
                © The Author(s) 2020. Published by Oxford University Press on behalf of the Society of Occupational Medicine. All rights reserved. For Permissions, please email: journals.permissions@oup.com

                This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                Page count
                Pages: 2
                Categories
                Editorials
                AcademicSubjects/MED00640

                Occupational & Environmental medicine
                Occupational & Environmental medicine

                Comments

                Comment on this article